

Prematurely ended-statement

EudraCT number	2020-002510-40
Full title of the study	A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.
Sponsor Protocol Code:	DEALSZ-2020-001
Study Contact	Prof. Dr. med. Marcus Maurer Campus Benjamin Franklin Institut für Allergieforschung Hindenburgdamm 30 12200 Berlin
Sponsor	Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin
Contact email address	marcus.maurer@charite.de
Product	Avdoralimab
Date of the early termination of the trial	07.07.2021
Statement on discontinuation of the study	The clinical trial was terminated prematurely in the initial phase because the sponsor stopped funding. No patients have been included up to this point.